Cangrelor is a direct P2Y12 platelet receptor antagonist administered parenterally during intervention. Co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with undergoing percutaneous coronary intervention (PCI).
